Bio-Technology General Corp. (NASDAQ:BTGC) announced thatFDA has granted its recombinant human growth hormone(rhGH) orphan drug designation as a treatment for cachexia(wasting syndrome) in AIDS patients.

The New York company has already demonstrated in pilotclinical studies that its rhGH can reverse this wasting, or severeweight loss, which is associated with a compromised immunesystem and greater susceptibility to opportunistic infections.BTG is currently testing its rhGH in Phase I studies in HIV-infected patients.

(c) 1997 American Health Consultants. All rights reserved.